Bacterial test method by glycated label binding

Abstract

A method for measuring the bacteria content of fluids such as urine and blood, in which a glycoprotein or glycopeptide is attached to the bacteria and a label attached to or inherent to the glycoprotein or glycopeptide provides a means for determining the amount of bacteria present. A preferred glycoprotein is alkaline phosphatase, which is an enzyme capable of attaching to all bacteria present in the fluid sample and inherently includes a label moiety in that color can be developed by addition of known reagents.

Description

BACKGROUND OF THE INVENTION

This invention relates generally to methods for detecting bacteria in fluids, particularly in biological specimens. More specifically, the invention relates to rapid methods for detecting all bacteria in urine and other fluids with improved accuracy compared to those currently available. Although analysis of urine is of particular interest, other fluids, such as blood, serum, water, and the like may be analyzed using the methods of the invention.

A rapid test for all bacteria is desirable, for example by using dry test strips of the sort now used for various purposes. At present, urine test strips are used to screen samples and rule out those which do not require laboratory assessment. However, the current tests, such as measurement of nitrites and leukocytes, are not capable of rapidly providing accurate results. These tests are indirect measures of bacteria and often, many false results are obtained, causing unnecessary laboratory follow-up analyses. About 50% of a hospital laboratory's workload involves urine specimens and about 90% of these specimens are cultured and analyzed for total and gram negative bacteria. However, only about 10% of urine samples which are cultured for detection of bacteria are actually found to test positive. Clearly, an accurate prescreening of urine could greatly reduce the number of samples sent to the laboratory for analysis.

The market penetration of the presently available test strips is not large, in part because the tests produce false positive results, as later determined by laboratory follow-up analysis. Thus, a test strip which provides rapid and accurate determination of the presence of bacteria would reduce costs and make it possible to treat bacteria in a patient immediately, rather than waiting for laboratory results.

The present inventors were investigating methods by which bacteria could be detected accurately. One potential approach involved finding substances that could bind to bacteria and then be detected and measured so that the amount of bacteria present could be determined. The problem can be stated as follows: How do substances bind to bacteria and which substances exhibit the properties needed for accurate measurements to be made? The binding should be specific to the bacteria. Non-specific binding can obscure the results since it can vary unpredictably and provide inaccurate results.

Antibodies are recognized as having the ability to attach to bacteria and it was believed that if ALP (alkaline phosphatase), which can be used to detect by color development materials to which it is bound, could be attached to another substance capable of attaching itself to bacteria, it would be possible to measure the amount of bacteria present. At first, experiments indicated that the ALP was bound to bacteria in a non-specific manner and therefore it was considered to present a problem to the development of a reliable method of measuring the amount of bacteria present in a sample. Further investigation was directed toward eliminating non-specific binding of ALP so that only the ALP attached to substances which could bind to bacteria would be measured. Surprisingly, it was found that the belief that the ALP was non-specifically bound to bacteria was not correct and that in fact, it did bind to bacteria, leading to the present invention. As will be seen below, ALP is a preferred substance for measuring the amount of bacteria, but other substances can be used, particularly glycopeptides and glycoproteins.

Related Literature and Patents

Methods for rapid testing for bacteria are known, but they differ from the method of the present invention. In one method, an immunoassay for detecting lipopolysaccharides from Gram negative bacteria such as E. Coli, Chlamydia or Salmonella uses a lipopolysaccharide binding protein or an antibody having specific binding affinity to the liposaccharide analyte as a first or second binding reagent (see WO 00/60354 and U.S. Pat. No. 5,620,845). In U.S. Pat. No. 5,866,344 other immunoassays are described for detecting polypeptides from cell walls. Proteins can be purified in a method using polysaccharide binding polypeptides and their conjugates (see U.S. Pat. No. 5,962,289; U.S. Pat. No. 5,340,731; and U.S. Pat. No. 5,928,917). In U.S. Pat. No. 5,856,201 detection of proteins using polysaccharide binding proteins and their conjugates is disclosed. The methods described in the above differ from those of the present invention, as will be seen in the discussion of the present invention below.

The methods which are based on liposaccharide antibodies or binding proteins do not provide a measure of the total bacteria present. They also do not use a glycopeptide or glycoprotein to bind to a bacteria cell. The methods based on polypeptides require antibodies to bind to the bacteria cell wall rather than using glycopeptides or glycoproteins. The methods based on polysaccharide binding polypeptides require the fusion of short sequences of polypeptides onto analytes of interest and employ non-glycated polypeptides to bind to a polysaccharide.

Glycoproteins have been shown to bind to various biomolecules. For example, glycoproteins on a fungus cell surface have been shown to bind to host proteins. Also, glycoproteins excreted from epithelial cells have been shown to bind to lipids and the binding of glycoproteins to carbohydrates is well known. All such interactions of glycoproteins are dependent on many factors, such as ionic strength and pH, and the affinity of the individual proteins for the biomolecules. However, the use of glycoproteins in assays for measurement of bacteria content has not been described heretofore.

Glycoprotein receptors have been isolated on human monocyte cells. Two binding proteins extracted from the cell walls of human monocytes have been shown to have an affinity of 9×10⁺⁶ for binding fructosyllysine (lysyl peptides glycated with glucose) with 10,000 active binding sites per cell. These receptor protein sites are thought to belong to the family of RNA-binding proteins and to be involved in the aging process by binding age related proteins such as glycated albumin. However, the prior art on glycoprotein does not teach that receptors on the cell walls could be used for the detection of cells. There is no means provided for signal generation, whether by color particle or enzymatic reaction that can be used as a measure of the count or detection of cells.

Bacteria are known to attach to host tissue, often by adhesion of bacterial cell membrane to extra-cellular matrix proteins of the host. This binding is known to occur through several modes of interaction, by glycoaminoglycans, collagens, proteins and integrins on their surface. Thus, the cell surface, including bacterial cell surfaces, can be visualized as a mosaic of molecules capable of binding to proteins of the host tissues as well as receptor sites of the host.

The interaction between bacterial cells and glycoproteins is known generally, but the binding of specific glycopeptides to a bacterial cell has not been disclosed. Bacterial cell adhesion has been described to extra-cellular matrix proteins such as fibronectin and lamin. This binding was shown to occur between the cell adhesions and glycated groups on the proteins. Similar results have been shown with connective tissue proteins and bacterial cells. Polypeptide and carbohydrate structures of glycoproteins can vary greatly and the chemical structures of glycopeptides and glycoproteins are often unknown, such as those which bind bacterial cells.

Methods for measuring binding of glycoproteins to bacterial cells have been described; however, the measurement of bacteria by glycopeptide or glycoprotein binding has not. More particularly, binding of glycopeptides or glycoproteins which are enzymes or are attached to detection labels has not been disclosed.

The binding of cell walls to alkaline phosphatase (ALP) is known, but at the present time, it is not possible to assign a precise function to any alkaline phosphatase other than the catalysis of the hydrolysis of phosphomonoester. It is known that tissue damage causes a release of these ALP iso-enzymes providing clinical significance.

Certain ALP iso-enzymes are known to be membrane-bound. Intestinal, liver, bone, kidney and placental alkaline phophatase iso-enzymes are examples of enzymes that are known to be membrane bound to cell walls, including dipeptidylpeptidase, aminopeptidases such as alanine aminopeptidase, endopeptidase, gamma-glutamyl transferase, lactase, alpha-D-glucosidases, hydrolases such as glycosidase and 5′ nucleotidase. Cell membrane binding for ALP is known to occur through a C-terminal glycan-phosphatidyl-inositol anchor in which the long chain triglycerides of the anchor are incorporated into the lipoprotein membrane. The C-terminal glycan-phosphatidylinositol anchor is absent from the ALP produced by E Coli bacteria and the ALP from E Coli is considered to be a soluble enzyme. Thus, binding of ALP to E Coli in the present invention would have to occur by another mechanism.

ALP has been used in some diagnostic applications. For example, ALP has been used in an immunoassay diagnostic test as a label for the immunoassay; see U.S. Pat. No. 5,225,328. However, it has not been used in a dry phase test without an antibody for detection of bacteria.

The present inventors have discovered that bacteria cells have the ability to bind certain glycoproteins through multiple binding sites. As a result of this discovery, they have found that such glycoproteins can be used in test strips having the ability to detect all bacteria present with accuracy, as will be seen in the detailed discussion of the invention which follows.

SUMMARY OF THE INVENTION

In one aspect, the invention is a method for measuring the bacteria content of a fluid, typically a biological fluid, in which an effective amount of a glycoprotein or glycopeptide is reacted with bacteria in a sample of the fluid, the glycoprotein or glycopeptide being labeled with a detectable moiety. Any excess of the glycoprotein which has not been reacted with bacteria is separated, after which the amount of the label moiety is measured and related to the amount of bacteria present in the sample.

The glycoproteins and glycopeptides generally consist of proteins or peptides linked through nitrogen or oxygen bonds to glycosidic groups selected from the group consisting of Gal, GlcNAc, SA, Man, Glc, GalNAc and combinations thereof. Such glycoproteins include serum proteins; immunoglobulins, oxygen-binding proteins, fibrous proteins, intercellular enzymes, hormones, secreted enzymes and inhibitors. Representative serum proteins include albumin, prealbumin, transferrin, retinal binding protein, bikunin, uristatin, alpha-1-Glycoprotein, alpha-1-antitrypsin, Tamm-Horsfall protein, beta-2-glycoprotein and fragments thereof. Representative immunoglobulins enzymes include IgG, IgA, IgM, IgD and gG. Representative enzymes include alkaline phosphatase, acid phosphatase, fucosidase, mannosidase, hexamimidase, alph-galactosidase, phospholipase, hyaluronidase, glucocerebrosidase, hydrolase, arylsulfatase A, amylases, cellobiohydrolase, trypsin, and peroxidase. Inhibitors include protease inhibitor. The glycoproteins and glycopeptides also include teichoic acid, lipoteichoic acid, and lectins.

In a preferred embodiment, the glycoprotein or glycopeptide contains a complex sugar chain including sialic acids (SA), and a reagent is added to develop color indicating the presence of glycoprotein or glycopeptide bound to bacteria. The association (binding) constant of the glycoprotein to bacteria should be at least 10⁺⁶ and the number of binding sites at least 100. In the preferred embodiment, the proteins contain a complex sugar that includes sialic acids (SA) and meets minimum association constants and binding site numbers. This protein can be derived from a protein that typically contains complex sugars. Some of the proteins containing this group include Tamm Horsfall Protein, Glycoproteins including all alpha and beta versions of I, II, III, IV, and V glycoproteins and leucine rich form, alpha-1-glycoprotein, beta-2-glycoprotein, acid-glycoprotein, alkaline phosphatase (ALP), urinary trypsin inhibitors including Bikunin, and Uristatin, Immunoglobulins including gG, IgG, IgD, IgA and IgM, cermloplasmin, mucin and fragments thereof.

Carbohydrate monomer units which may be attached to proteins may be galactose (GAL), mannose (MAN), glucose (GLC), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), sialic acids (SA), fucose, and xylose.

Representative glycopeptides include Y-Ser-X₂, Y-Thr-X₂, Y-Asn-X₂, Y-Lys-X₂ and Y-Hyl-X₂- where X may be any amino acid and Y may be Man, Gal, Glu, SA, GlcNAc, GalNAc, fucose or xylose as the attachment site for the carbohydrate chain. The carbohydrate chain is complex sugar that may have a wide variety of lengths and combinations of Y and includes at least one SA. The chains can be can be single strands or branched chains such as bi-antennary, tri antennary, and tetra-antennary structures.

Label moieties which may be added to glycoproteins include radioactive, fluorescent, electroactive, chem-luminescent, enzymes, antibodies, and particulate labels. Blocking compounds may be included, such as members of the group consisting of polymers, non-glycated proteins, non-glycated polypeptides and polysaccharides. Cations may be added, especially zinc, copper, iron, and cobalt to increase the binding of the glycoprotein or glycopeptide to bacteria.

In another aspect, the invention is a dry test method for measuring the bacteria content of a fluid wherein a glycoprotein or glycopeptide containing a label moiety is bound to the bacteria and the label moiety measured to determine the bacteria content of the fluid sample.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Tamm-Horsfall Protein.

FIG. 2 Urinary trypsin inhibitor (Bukinin/uristatin)

FIG. 3 Alkaline phosphatase

FIG. 4 Alpha-1-acid glycoprotein

FIG. 5. Peptidoglycan layer of all bacteria cells

FIG. 6 Lipopolysaccharide of gram negative bacteria

FIG. 7. Lipoteichoic acid of gram positive bacteria

FIG. 8 illustrates the results of Example 1

FIG. 9 illustrates additional results of Example 1.

FIG. 10 illustrates the results of Example 4.

FIG. 11 illustrates the results of Example 7.

FIG. 12 illustrates the results of Example 7.

FIG. 13 illustrates the results of Example 8.

FIG. 14 illustrates the results of Example 8.

FIG. 15 illustrates the effect of pH on ALP activity.

FIG. 16 illustrates the effect of pH on ALP activity.

FIG. 17 illustrates the effect of different cations on ALP binding.

FIG. 18 illustrates the effect of different cations on ALP binding.

While the invention is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of examples described in detail herein. It should be understood, however, that the invention is not intended to be limited to the embodiments disclosed, rather, the invention is defined by the appended claims.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Glycoproteins and Glycopeptides

Both glycoproteins and glycopeptides are composed of amino acids with peptide linkages and carbohydrates. Generally glycoproteins have higher molecular weights than glycopeptides. Glycoproteins and glycopeptides can be attached to bacteria through charge attraction and shape to molecules on the cell wall. As will be seen in the examples below, the amount of the glycoprotein or glycopeptide bound to bacteria cells will vary depending on several factors, including the molecular structure, presence of metals, ionic strength, and pH of the environment.

Glycoproteins, in which one or more carbohydrate units have been attached covalently to the protein, are a widely varied group of biomolecules. Most secretory proteins, and their fragments, are glycoproteins, as are components of membranes such as cell receptors, where the carbohydrates are involved in cell to cell adhesion. Most proteins that are secreted, or bound to the plasma membrane, are modified by carbohydrate attachment. Intracellular proteins are less frequently modified by carbohydrate attachment. However, the attachment of carbohydrates to intracellular proteins does occur and provides unique activities.

Linkage of carbohydrates to proteins occurs via O-glycosidic or N-glycosidic bonds. The N-glycosidic linkage can be through the amide group of asparagine or the free amine of lysine. The O-glycosidic linkage is to the hydroxyl of serine, threonine or hydroxylysine. The linkage of carbohydrate to hydroxylysine is generally found in collagens. The linkage of carbohydrate to hydroxylysine is either the single sugar galactose or the disaccharide glucosylgalactose. In ser- and thr-type O-linked glycoproteins, the carbohydrate directly attached to the protein is typically GalNAc. In arg-type N-linked glycoproteins, it is typically GlcNAc.

The carbohydrate monomer units that are commonly attached to proteins include galactose (Gal), mannose (Man), glucose (Glu), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (Gal NAc), sialic acids (SA), fucose and xylose. The carbohydrate chains occur with a wide variety of lengths and structures, but some typical structures encountered are Man-GlcNAc-, GalNAc(Gal)(SA)-, Man(Man(Man)₂), (Man(Man))-GlcNAc, -GlcNAc-Man((Man-GlcNAc-Gal-SA)₂, -GlcNAc-GlcNAc and those represented in the various glycoforms of glycoproteins listed in Table 2 below. Glycoproteins are heterogeneous mixtures of multiple glycoforms resulting from post-translation modifications altering the carbohydrate sequence.

All glycoproteins found naturally have preferred residues for attachments within the peptide chains, preferred carbohydrate ordering within the chain and preferred types of carbohydrate modification. For example, carbohydrate chains are generally attached to proteins and peptides via the hydroxyl groups of serine (Ser) or threonine (Thr) amino acid residues, the amide N atom of asparagine (Asn) side chains or through hydroxy-lysine (Hyl) residues. The particular Ser and Thr residues O-glycosylated do not appear to occur in unique amino acid sequences, therefore Ser or Thr can be connected to any aminoacid, such as Ser-X, Thr-X, where X can be any amino acid. The glycosylation of Hyl residues occurs in a characteristic sequence -Gly-Y-Hyl-Z-Arg-, where Y and Z are any amino acids. The Asn residues N-glycosylated occur in the sequence of -Asn-X-Ser- or -Asn-X-Thr-, where X may be any of the normal amino acids, other than Pro.

The predominant carbohydrate attachment in glycoproteins of mammalian cells is via N-glycosidic linkage. O-linked glycoproteins are built via the stepwise addition of nucleotide-activated sugars directly onto the polypeptide. The attachment of sugars is catalyzed by specific glycoprotein glycosyltransferases. N-linked glycoproteins generally contain a common core of carbohydrate attached to the polypeptide. This core generally consists of three mannose residues and two GlcNAc. The carbohydrate chains include four major types: Simple carbohydrates; high-mannose type containing all mannose outside the core in varying amounts; hybrid type containing various sugars and amino sugars and; complex type which is similar to the hybrid type but contains sialic acids. The carbohydrate modifications found in glycoproteins are rarely complex. Glycoproteins with sialic acid removed by treatment with enzyme or mild acid are designated by the prefix asialo-, e.g. asialo alph₁-acid glycoprotein.

Proteins having complex type carbohydrate chains include Tamm-Horsfall protein (THP; uromucoid), α-1-acid glycoprotein (AGP; orosomucoid), human immunoglobulin (IgG), and urinary trypsin inhibitors (uTi, Bukinin and Uristatin) (Table 2). All of these proteins are known to have hybrid type carbohydrate chains which lack sialic acids (asialo) and complex types containing sialic acids.

Also these proteins contain multiple types of carbohydrate attachments and have a great number of known variations of carbohydrate chains (glycoforms). For example, Tamm-Horsfall protein has one high-mannose type chain and multiple N-linked of the hybrid type (FIG. 1). Urinary trypsin inhibitor and human ALP can contain both O-linked and N-linked complex and hybrid carbohydrate chains (FIGS. 2 & 3). Urinary trypsin inhibitors that include two glycoconjugate chains and two Kunitz inhibitor are called Bikunin (see Fries, Pugia). New forms of urinary trypsin inhibitors (Uristatin) were recently discovered in acute phase infections that contains either Kunitz inhibitor domains but always lacks the O-linked glycoconjugate chain (see Pugia, Jorani, Pugia). The N-linked glycan of uTi has been reported to have a bi-antennary structure (see Kato, Hochstrasser, Suzuki) The number of glycoforms of uTi is currently unknown. Tamm-Horsfall protein has five N-linked glycan chains that can be bi-, tri- and tetra-antennary complexes (see De Graaf, Cioci, Fukuoka) (FIG. 1). The number of glycoforms of THP has also not been determined although it is known to be highly donor dependent (see Afonso). AGP has five N-linked glycan chains that can be bi-, tri- and tetra-antennary complexes with 40 known glycoforms of which the bi-antennary complexes are rare (see Azuma, Nishi, Kopeck, Higai) (FIG. 3). ALP has one N-linked glycan chains that can be a bi-antennary complexes and a N-linked glycan GPI that is not present in bacterial ALP isoforms (see Blom, Fukushima) (FIG. 4).

Other glycoproteins are formed by non-enzymatic reactions between carbohydrates and the N-terminal amino acid groups or lysine residues of protein. This attachment can occur in the body between serum protein and carbohydrates. This is especially true in diabetic plasmas where non-enzymatic glycation occurs for immunoglobulins, hemoglobin, albumin, complement C3, fibrinogen, transferrin, haptoglobin, and alpha-1-antitrypsin, prealbumin (transthyretin precursor) and Retinol Binding Protein to form advanced glycation end (AGE) glycoproteins. Most of these AGE glycoproteins have single carbohydrate units. Alpha-1 antitrypsin has a high mannose structure

Glycoproteins both play a role in the body's defense mechanisms through cell membrane binding. The N-glycan of THP has hema-agglutination properties as influenza virus binds to sialic acid thorough the neuamimidase-type glycoprotein on the virus cell membrane (see Higai, Kunin, Strauss). THP also has one O-linked proteoglycan chain involved in membrane bound (see De Graaf, Cioci) and one N-linked high mannose chain with E. Coli binding properties (see Kunin, Cavallone). AGP is an acute phase protein with membrane binding properties that modulate monocytes, granulocytes and lymphocytes binding to the endothelial (see Fournier, Afonso). Immunomodulatory activity of AGP is dependent on gylcoslation, with formation of sialy Lewis X leading to endothelial cell adhesion through P- and E-selectins thereby blocking immunocell adhesion (see Fournier). The sialy Lewis X is known to bind to influnenza virus (see Higai). Expression of sialy Lewis X and bi-tetra-antennary complexes of AGP is known to increase early on with inflammation (see De Graaf) while greater fucosylation occurs with diabetes (see Higai). The role of the N-glycan of uTi is not currently known although similarly several acute phase processes could be implicated.

One particularly effective glycoprotein in the invention is alkaline phosphatase (ALP) with one N-linked hybrid carbohydrate chain with SA units. The peptide sequence of ALP is known to range from between 29 and 729 peptides. ALP has the advantage of being capable of binding to bacteria and inherently providing a label moiety due to enzymatic activity that can be developed by addition of known reagents, a technique used in immunoassay diagnostic tests. The amount of the glycoprotein will depend upon the amount of the bacteria present in the sample; for example, when bacteria is present, a certain amount of glycoprotein will be bound, depending on the number of binding sites and strength of the binding constant. With a given glycoprotein and bacteria cell type the number of binding sites is fixed and the amount of glycoprotein bound is directly proportional to the amount of bacteria present.

Bacteria Cell Wall Composition

All bacterial cell walls contain a peptidoglycans (PG) shell. This shell consists of peptide units of adjacent polysaccharides (glycosaminoglycans) that are cross-linked by a peptide bond between the C-terminal alanine residue of one peptide subunit and the diamino-acid residue of the other (e.g. L-lysine or meso-diaminopimelic acid), forming a giant macromolecule structure for a rigid cell wall (See FIG. 5). The peptidoglycans shell occurs as a monomolecular layer between the inner and outer membrane in Gram-negative bacteria and has exposed areas where the outer layer is absent. The outer layer of Gram-negative bacteria is lipopolysaccharide (See FIG. 6). The peptidoglycans shell occurs as the outer membrane in Gram-positive bacteria and is associated covalently or non-covalently with various additional compounds (lipoteichoic acids, neutral polysaccharides, etc.) in Gram-positive bacteria (See FIG. 7).

Common peptidoglycan structure and variations have been characterized in thousands of bacterial strains. The existence of more than 100 chemotypes in the bacteria are known. However, the peptidoglycans of bacteria are all classified into two major groups (A and B) and several subgroups according to the mode of cross-linkage. In group A is cross-linked by lysine or alanine residue cross-linked to a peptide on the adjacent polysaccharide. Variations in the interpeptide cross-linkages depend on the peptides linked and the positions of attachment. All interpeptide cross-linkages must contain a diamino acid, which may be lysine, ornithine or diaminobutyric acid, in either L- or D-configuration. In Group B peptidoglycan types, the L-alanine residue of the peptide subunit is replaced by either glycine or serine.

Label Moieties

Alkaline phosphatase is particularly useful, as mentioned above, since it inherently provides a label. Other glycoproteins or glycopeptides may not have the inherent ability to serve as a label as well as binding to the bacteria. Thus, in those instances, label moieties may be added so that the amount of the glycoprotein or glycopeptide can be measured to indicate the amount of the bacteria present. Examples of such label moieties which may be useful include colorimetric, radioactive, fluorescent, electrochemical signal transducers based on amperometric, impedimetric, potentimetric, chem-luminescent, and particulate labels.

Antibodies to the glycoprotein are particularly useful as labels for detection. The antibody can be free or conjugated (labeled) with reagents that directly or indirectly produce detectable responses, other antibodies or other reagents in a variety of fashions. Rare earth metals label assays, chemiluminescence assays (CLA) and optical color label assays (OA) such as colored latex particle and colloidal particles all serve as known antibody labels.

Separation Methods

The determination of free versus bound glycoproteins requires a separation step. Multizone assays are particularly useful for separation and can be flow through or lateral flow formats with many types of filters used. There are various types of multizone immunoassays that could be adapted to this separation. In the adaptation of immunochromatography assays, reagent filters are placed into separate zones and chromatographic, capillary and gravity forces used to accomplish the separation. Antibodies to the glycoprotein can serve as affinity labels for separation. See, for example: Greenquist in U.S. Pat. No. 4,806,311, Multizone analytical Element Having Labeled Reagent Concentration Zone, Feb. 21, 1989; Liotta in U.S. Pat. No. 4,446,232, Enzyme Immunoassay with Two-Zoned Device Having Bound Antigens, May 1, 1984. In another adaptation, size exclusion can be used to separate the bacteria with bound glycoprotein from the free glycoprotein. The pore size of the filter is adjusted to prevent cells from flowing through the zone. Separation steps are possible in which an analyte is reacted with reagent in a first zone and then the reacted reagent is directed to a second zone for further reaction. In addition a reagent can be re-suspended in a first zone and moved to a second zone for a reaction. An analyte or reagent can be trapped in a first or second zone and a determination of free versus bound reagent be made.

Additional Components

The method of the invention may be applied in dry test strips familiar to those skilled in the art, or in wet test methods such as those described in the examples below. Depending on the specific technique, buffering compounds, substrates for the glycoprotein or glycopeptide, enzyme amplification compounds, and other additives such as blocking compounds may be present.

It has been discovered that adding specific transition state metals increase protein binding to bacteria cell walls . . . While not required, the use of specific transition state metals increases the sensitivity of an assay based on glycated protein binding to bacteria.

In a particularly preferred embodiment of the invention, such metals are used to increase the response of the labeling moiety. Various metals have been evaluated. Of these, zinc, copper, iron, and cobalt have been found to have a particularly beneficial effect as will be seen in the examples below.

Blocking compounds selected from the group consisting of polymers, non-glycated proteins, non-glycated polypeptides, and polysaccharides may be included in order to reduce interference or improve color. Interference is improved by preventing non-specific binding by interfering substances to bacteria by instead binding interfering substances to the blocking compound. Color is improved by acting as a spreading layer that allows color to be uniform in dry reagents.

There are various reagent methods which could be used as part of the labels of the invention. Reagents undergo changes whereby the intensity of the signal generated is proportional to the concentration of the analyte measured in the clinical specimen. These reagents contain indicator dyes, metals, enzymes, polymers, antibodies, electrochemically reactive ingredients and various other chemicals dried onto carriers. Carriers often used are papers, membranes or polymers with various sample uptake and transport properties. They can be introduced into the reagent zones of the invention to overcome the problems encountered in analyses using reagent strips.

Additional Components for ALP

Substrates for ALP include the phosphate esters of the following organic groups: primary and aliphatic alcohols, sugars, sugar alcohols, phenols, naphthols and nucleosides. Examples of substrates forming visual color include naphthol-AS-BI-phosphate, naphthol-AS-MX-phosphate, p-nitrophenol phosphate phenylphosphate (PPNP), indoxylphosphate, e.g., bromo-chloro-indolyl-phosphate (BCIP), phenolphthalein phosphate, thymolphthalein monophosphate and diphosphate, beta-naphthylphosphate, dicyclohexylammonium salt of PPNP for stability, thymolphthalein monophosphate, phenolphthalein diphosphate, carboxyphenyl phosphate, beta-glycerophosphate and beta-glycerolphosphate. Examples of fluorescent substrates for ALP include methylfluoresceine alpha-naphthyl phosphate. Alkaline phosphatase can be measured by a wide range of chemiluminescent and bioluminescent substrates. Examples of chemiluminescent substrates for ALP include adamantyl 1,2-dioetane aryl phosphate, 5-bromo-4-chloro-3-indolyl phosphate, phenacyl phosphate, NADP, ascorbic acid 2-O-phosphate, cortisol-21-O phosphate, N,N′-dimethyl-9,9′ bisacridinium dinitrate, indolyl derivatives, e.g., 5-bromo-4-chloro-3-indolyl phosphate disodium salt (BCIP-2Na), D-luciferine-O-phosphate and adamanyl 1,2-dioxetane aryl phosphate (AMPPD).

Various buffers, both non-transphosphorylating and those of varying degrees of transphosphorylating property have been used for ALP determinations (i.e., Carbonate, 2-amino-2-methyl-1-propanol and diethanolamine). Buffers commonly utilized for ALP include ethylaminoethanol (pKa 9.9), diethanolamine (pKa 8.7), tris-(hydroxymethyl) aminomethane (pKa 7.8), 2-amino-2-methyl-1-propanol MAP. (pKa 9.3), 2-amino-2-methyl-1,3-propanediol (pKa 8.6), sodium carbonate, sodium bicarbonate (pKa 9.9), glycyl-glycine (pKa 8.2), glycine (pKa 9.6), and barbital (pKa 7.44) with activity measured at pH ranges of 7 to 10.

Additional additives such as enzyme co-factors may be used to enhance the reaction conditions for enzymes. Mannitol and other alcohols can be used to increase ALP substrate rates. In the case of ALP, at least one equivalent of Zn, Ca and Mg metal for each ALP molecule will be present to provide catalytic activity and possibly also for maintenance of the native enzyme structure. Enzyme inhibitors are also often used to modulate enzyme assay ranges and mask interference. In the case of ALP, known inhibitors include cysteine, EDTA and thioglycolic acid, L-phenylalanine, L-homoarginine, L-tryptophane, L-leucine, levamisol and imidazole. It is also known that salts such as sodium chloride can be used to control enzymes. It is also known that surfactants such as sodium dodecyl sulfate and bile acids modulate enzyme assay ranges and sensitivity.

Enzyme amplification systems can also be used to increase detection limits for enzyme assays. Several enzyme amplification methods for the detection of alkaline phosphatase are known. These include the formation of formazan (INT-violet colorimetrically or resazurin fluorimetrically) through enzyme systems (e.g., diaphorase and alcohol deyhydrogenase) that employ NAD co-factor and rely on ALP to dephosphorylate NADP enzyme to produce NAD. For example, nicotinamide adenine dinucleotide phosphate (NADP) conversion to NAD⁺ by ALP has been used for amplification. The NAD⁺ compound was then reduced to NADH by alcohol dehydrogenase in the presence of ethanol included in the reaction medium. In turn, NADH in the presence of diphorase was converted back into NAD with simultaneous reduction of tetrazolium salt also present in the medium. This resulted in an accumulation of colored soluble formazen dye, proportional to the concentration of NAD⁺ generated by AP. The newly formed NAD⁺ is recycled many times, resulting in a 100-fold increase in sensitivity.

Test Methods

The use of glycoproteins for the detection of bacteria can be applied to a variety of test methods. The methods require combining a glycoprotein with sample to be assayed, separating the glycoprotein bound to bacteria from free unbound glycoprotein and measuring bound or free glycoprotein. Such steps can be accomplished through a variety of fluid handling analyzers such as chromatography strips, flow through strip, capillaries, microfluidic chip devices, centrifugation, filtration and microplates, to name a few. Bacteria sizes of 10-30 micron can be separated.

The effectiveness of glycoproteins for the detection of bacteria is measured in the same way for all test methods. Effectiveness is measured by obtaining a bacteria detection signal that is three standard deviations from the signal obtained in the absence of bacteria.

There are several methods used to measure binding affinity. The methods of Lineweaver-Burke and Eadie-Hofstee are most popular. The data is used to create a Scatchard plot, where the X axis is the glycoprotein bound and the Y axis is glycoprotein bound divided by the free glycoprotein. From this graph the number of binding sites (also called Bmax, receptor number) is the X intercept and binding constant (also called affinity constant, Kd, or the equilibrium dissociation constant) is the negative reciprocal of the slope. Changes in slope reflect changes in the nature of binding sites and are often used to separate high affinity binding from low affinity binding sites. Commercially available software (GraphPad software Inc) exist to perform this analysis. Only high affinity binding was used in the instant experiments.

Experimentally, saturation binding experiments are used measure glycoprotein binding at equilibrium at various concentrations of the glycoprotein. The saturation curve is a first constructed to plot the concentration of glycoprotein ligand on the X axis versus the all glycoprotein bound on the cell expressed as concentration of glycoprotein bound/number of bacteria cells on the Y axis. A reasonable initial Bmax value is half of the maximum Y value observed. This same data is next plotted as a Scatchard plot with the number of binding sites and binding constants determined for the pairs of glycoprotein and bacteria tested. The binding depends on incubation to proceed to equilibrium. For glycoprotein binding to be useful to a clinician the maximum time allowed was 30 minutes at room temperature. The lowest concentration of glycoprotein took the longest to equilibrate, therefore the low concentration of glycoprotein used was 10-20% of the Kd.

In order for the glycoproteins to be effective at detecting 1000 bacteria cell/mL, the association constant must be at least 1×10⁺⁶ and the number of binding sites at least 100. This was determined by setting alkaline phosphatase as the minimium needed based an on analysis time of 30 minutes and a detectable signal to noise ratio of 6. The Scatchard analysis was used to measure of the binding strength of glycoprotein to bacteria and of the number of binding sites for glycoprotein to bacteria allow a sufficient bacteria detection signal. The 1000 bacteria cell mL detection limit is the minimal clinically desired threshold. A sufficient background reading for the glycoprotein binding to other specimen components, e.g., other proteins, must be an association constant of less than 10⁺⁴. Using ALP as a representative example, a binding constant of 5×10⁺⁶ and the number of binding sites was estimated to be 590 from the Scatchard analysis.

Competititive inhibition of ALP binding to bacteria was another method used to establish whether a particular glycoprotein has binding strength comparable to ALP. A glycoprotein capable of completely inhibiting ALP binding has a binding constant greater than 5×10⁺⁶ and a number of binding sites greater than 590. A glycoprotein capable of inhibiting ALP binding by at least 50% has an estimated binding constant of at least 1×10⁺⁶ and a number of binding sites at least 100. Less than 20% was no inhibition (NI) and greater than 90% was complete inhibition (CI) with a binding constant great than ALP.

EXAMPLE 1

Bacteria Assay by Binding of Intestinal Alkaline Phosphatase

Bacterial cells (106 to 10⁸ cells/mL) were washed twice with water after centrifugation to separate the cells into a packed pellet from supernatant liquid. The washed cells in pellet form were suspended in 40 μL water and 10 μL of aqueous bovine intestinal alkaline phosphatase (ALP) was added (2 μg or 10,000 Units). The mixture was left at room temperature for 30 minutes and then centrifuged, after which the bacterial pellets were washed with water 4-5 times (50 μL). All the washing supernatants were combined. A blank without cells was diluted in the same way. The final pellets were suspended in 50 μl water and both supernatants and cell suspensions were assayed for detection of ALP binding using 2.5 μl of 0.005 M para-nitrophenol phosphate (PNPP) in Tris or EPPS buffer at pH 7.5. The hydrolysis of the substrate results in yellow (PNPP) or blue-green (BCIP) color that is directly proportional to the amount of ALP bound to the bacteria. Alkaline phosphatase (ALP) activity was tested using common substrates such as BCIP (bromo-chloro-indolyl-phosphate) forming a blue/green color in Tris buffer, pH 7.5. After 10 minutes at room temperature the samples were read in a plate reader (Biotek Powerwave Absorbance Reader) at a wavelength of 405 nm. The parallel set of bacteria was run without addition of ALP as controls.

Intestinal ALP binding to bacteria cells was observed. In FIG. 8, the striped bars show that suspended cells after ALP treatment and washings had more intestinal ALP activity than untreated cells (the solid bars). The solid bars do show that suspended cells not treated with intestinal ALP did have some ALP activity, believed to be from native ALP in the bacteria. As a control, the ALP activity of the treatment solutions show the maximum activity expected without contribution from native ALP.

FIG. 8 demonstrates intestinal ALP binding to all bacterial strains tested. Both gram positive bacteria such as Staphylococcus aureus (Sf) strains # 3 and #6 and gram negative bacteria such as Escherichia Coli (E. Coli) strains # 9 and 14 were found to bind the ALP. Again the striped bars being significantly larger than the solid bars demonstrate this. FIG. 9 shows that the amount of ALP bound or activity generated is directly proportional to the amount of bacteria cells present. The ALP activity of the suspended cell increased with increasing amounts of cells.

The mechanism of the binding of ALP to the bacterial cells is not fully understood, but it is believed that glycated peptides in ALP or other glycoproteins are binding to the peptidoglyan membrane. Both gram positive and gram negative bacteria are known to have peptidoglyan membrane. For gram negative bacteria, the outer lipopolysaccharide membrane is known to have openings to the peptidoglyan membrane. For gram positive bacteria the peptidoglycon membrane is the outer membrane.

The experiments reported show that alkaline phosphatase (ALP) was bound to both gram-negative and gram-positive bacteria. The bacteria used to illustrate the invention represent the extremes of gram positive (S. facaelis) and gram negative (E. coli) bacteria. Consequently, these results showed two very different bacteria strains are bound by glycoproteins/glycopeptides. It was also that ALP binding occurred to all other gram negative and positive bacteria in tested (Table 1). The nature of the difference in the cell walls is greatest between the gram negative and positive forms of bacteria. As changes of strain between gram negative and positive forms of bacteria did not greatly impact the ALP binding (withing 12% of S. facaelis or E. coli), the gram positive (S. facaelis) and gram negative (E. coli) bacteria were used for all further testing.

TABLE 1
Gram negative and gram positive pathogens
compared to Sf and E. coli for ALP binding
Gram-positive bacteria (GPB)     ALP binding relative to sf.
Enterococcus sp.                 100%
Group B streptococcus            96%
Coagulase negative staphylococcus sp. 88%
Yeasts including Candida albicans 93%
Streptococcus viridans           102%
Staphylococcus aureus & saprophyicus 100%
Lactobacillus                    100%
Gram negative bacteria (GNB)     ALP binding relative to E. coli
Escherichia coli                 100%
Klebsiella pneumoniae            105%
Citrobacter koseri               93%
Citrobacter freundii             89%
Klebsiella oxytoca               111%
Morganella morganii              95%
Pseudomonas aeruginosa           99%
Proteus mirabilis                104%
Serratia marcescens              101%
Diphtheroids (gnb)               91%

EXAMPLE 2

Bacteria Assay by Binding of Non-Glycated Protein to Bacteria

As a control, an enzymatic protein lacking glycation, beta-galactosidase, was tested for binding to bacteria cell walls. The bacteria from both Staph. and E. coli were tested for beta-galactosidase binding. The beta-Galactosidases (20 mU) were added to saline suspensions of 10⁸ cells/mL of both bacteria and were assayed as well as the pellets (cells re-suspended in water) and supernatants after spinning the bacteria using dimethylacridinium B-D-galactose (DMAG) as the substrate. The assay to determine the amount of enzyme was to add 10 μL of aqueous DMAG (0.5 mM) and 5 μL of aqueous tris buffer (1M) adjusted to pH 7.5 or test bacteria (10⁷ cells) and H₂O to 100 μl. Bright yellow color of DMAG changes to light green to dark blue in 5-30 minutes (with beta-galactosidase in 5 min) which is read at 634 nm on a plate reader. Beta-D-galactosidase is a non-glycoprotein and non-membrane protein. In these experiments, beta-D-galactosidase did not bind bacteria and no measurement of bacteria was possible.

EXAMPLE 3

Bacteria Assay by Binding of Glycated Proteins to Bacteria

Bacterial cells (1 to 4.5×10⁷ cells/mL) were washed twice with water after centrifugation to separate cells into a packed pellet from the supernatant liquid. The washed cells in pellet form were suspended in 20 ul of N-2-hydroxyethyl piperazine-N′-[3-propane sulfonic acid] EPPS buffer (50 mM at pH 8.0) and 30 μL of water. Glycated protein(s) (2-40 μg) were added. In some cases a glycated protein (2-40 μg) and bovine intestinal alkaline phosphatase (ALP) (2 μg or 10,000 Units) were added and the binding of the glycated protein measured by the reduction of binding of ALP.

The mixture of glycated protein and bacterial cells was left at 25° C. for 15 minutes. The mixture was then centrifuged at 30,000 rpm for 30 minutes after which the bacterial cells formed a pellet at the bottom of the tube and were washed with water 4-5 times (50 μL). Centrifugation allows separation of glycoprotein bound to the bacteria cells from unbound glycated protein(s).

After washing, the bacterial pellets were suspended in 50 μL of borate buffer (25 mM at pH 9.0). A 5 μL aliquot of the suspension was assayed for detection of ALP binding by adding 5 μL of para-nitrophenol phosphate (PNPP, 100 mM), 50 μL sodium borate buffer (25 mM at pH 9.0) and 140 μL of water. The hydrolysis of the PNPP substrate resulted in a yellow color. The color is read at 405 nm using a ELISA plate reader between 15-30 min. The absorbance is directly proportional to the amount of ALP bound to the bacteria cell adhesions for glycated groups.

Various glycated and non-glycated proteins were tested for binding to bacteria (See Table 2). Albumin, prealbumin, alpha-1-antitrypsin, alpha-1-microglobulin, retinol binding protein, alpha-1-acid glycoprotein, alpha-2-glycoprotein, transferrin, Tamm-Horsfall glycoprotein and immunoglobulins were all known glycated proteins as received from suppliers. Hemoglobin, lysozyme, and myoglobin are all known non-glycated proteins as received from suppliers. All proteins were found to be binding the bacteria cell by measurements of bound protein using comassie brilliant blue as a label.

Only a protein binding to the cell adhesions for glycated groups causes the inhibition of the binding of ALP by bacteria. A protein binding to the cell adhesions for glycated groups provides a positive number in Table 2. For example, albumin prevented 50% of ALP from binding to E. Coli bacteria and therefore meet the minimum binding criteria. As seen in Table 2 all glycated proteins inhibited the binding of ALP by bacteria and met the minimum binding criteria except THP with E Coli. This demonstrated that these glycoproteins can be used in the invention to detect bacteria. Uristatin, bikunin and α-1-glycoprotein were better binders than ALP. Removal of SA group from these proteins with neuramimidase reduced inhibition to 50%, therefore the SA groups were preferred for binding. Fragmentation of the Uristatin peptide chain with protease did not impact the inhibition, indicating the a specific protein backbone was not preferred for binding. Non-glycated proteins such as hemoglobin, myoglobin and lysozyme did not inhibit the binding of ALP. As a control, three non-glycated polypeptides (polyarginine, polylysine, polyhistidine) were tested and not found to inhibit ALP activity.

TABLE 2
Demonstration of binding of glycated proteins to bacteria
Glycoprotein added	E. coli	S. faec.	Carbohydrate Structures
Tamm-Horsfall protein	40%	49%	One high-mannose and
(THP)			Five complex or hybrid
			type
α-1-Antitrypsin	84%	74%	One complex type
Uristatin	>90%	>90%	One N linked complex
			type
Bikunin	>90%	>90%	One N and O linked
			complex type
α-1-glycoprotein (AGP)	86%	>90%	Five complex or hybrid
			type
IgG, IgA, IgM	63%	71%	One N-link complex type
beta-2-Glycoprotein	74%	61%	One N-link complex type
Transferrin	75%	75%	Simple carbohydrates
Retinol Binding Protein	81%	83%	Simple carbohydrates
Albumin	50%	61%	Simple carbohydrates
Prealbumin	50%	57%	Simple carbohydrates
Non-glycoprotein added
Polylysine, poly arginine,	<20%	<20%	non-glycated
poly histidine
Myoglobin	<20%	<20%	non-glycated
Hemoglobin	<20%	<20%	non-glycated
Lysozyme	<20%	<20%	non-glycated
*Less than 20% was considered no inhibition (NI) and greater than 90% was considered complete inhibition (CI)

As can be seen, a range of glycated proteins can bind to bacteria and be used to determine the amount of bacteria present in a sample. All of these glycoproteins can be modified such as by fragmentation of unneeded peptide sequences, through enzymatic or synthetic attachments of additional carbohydrate units, or by addition of labels. Modifications can be made to enhance binding and detection. ALP is an example of a glycated protein having enzymatic functionality and generating a signal, as demonstrated in Example 1. Other examples of enzymatic glycated proteins include acid phosphatase, fucosidase, mannosidase, hexamimidase, alpha-galactosidase, phospholipase, hyaluronidase, glucocerebrosidase, hydrolase, arylsufatase A, amylases, cellobiohydrolase, and peroxidase.

Alternatively, glycated proteins may be labeled to provide a signal indicating the amount which has been attached to bacteria, for example the comassie brilliant blue used in Example 3. Other labels could be a chromogen, an enzyme antibody with label, or a particle such as gold sol or colored latex. Common labels include radioactive, fluorescent, electroactive or chemi-luminescent compounds, enzymes, and particulates. For example a blue latex particle of 250 nm diameter was added to Uristatin to label the glycoprotein for detection measure free vs. bound. Additionally an antibody to Uristatin was used to measure the free vs. bound by reacting with Uristatin.

Blocking additives can be used to block competing reactions and reduce interference or act as spreading agents. Examples are the non-binding glycoproteins of Example 3. Others are polymers such as poly (vinyl pyrrolidone) or polyvinyl alcohol and proteins such as casein, gelatin, albumin, hydrophobic cellulose, and polysaccharides.

EXAMPLE 4

Bacteria Assay by Binding of ALP Iso-Forms to Bacteria

Bacterial cells (1 to 4.5×10⁷ cells/mL) were washed twice with water after centrifugation to separate cells into a packed pellet from the supernatant liquid. The washed cells in pellet form were suspended in 20 μL of EPPS buffer (50 mM at pH 8.0) and 30 μL of water. Hemoglobin (20 μg) was added as a blocking additive. Alkaline phosphatase (ALP) (100 mUnits) from intestine, placenta, and bacteria sources were added.

The mixture of glycated protein and bacterial cells was left at 25° C. for 15 minutes. The mixture was then centrifuged at 30,000 rpm for 30 minutes after which the bacterial cells formed a pellet at the bottom of the tube and were washed with water 4-5 times (50 μL). Centrifugation allows separation of glycoprotein bound to the bacteria cells from unbound glycated protein(s).

After washing, the bacterial pellets were suspended in 50 μl of sodium tetraborate buffer (25 mM at pH 9.5). A 5 μL aliquot of the suspension was assayed for detection of ALP binding by adding 5 μL of para-nitrophenol phosphate (PNPP, 100 mM), 50 μL sodium borate buffer (25 mM at pH 9.0) and 140 μL of water. The hydrolysis of the PNPP substrate resulted in a yellow color. The color is read at 405 nm using an ELISA plate reader between 15-30 min and the absorbance is directly proportional to the amount of ALP bound to the bacteria-cell adhesions for glycated groups. The results are illustrated in FIG. 10.

A comparison of ALP isozymes from placenta, bacterial and intestine sources allows an understanding of what glycosylation is needed for binding. The ISO forms of intestinal, liver, bone, and placental ALP have differences in carbohydrate structures and amount of sialic acid. Intestinal ALP lacks terminal sialic acids on its carbohydrate chains while placenta and bacterial have sialic acid residues. Bacterial ALP lacks a membrane binding glycophospholipid portion present in the mammalian ALP. Placenta ALP contains fucose, mannose and galactose while intestinal ALP has a high hexose and hexoamine content.

According to FIG. 10, the glycophospholipids are not requirements for glycoprotein binding to bacteria as the bacterial ALP binds bacteria but lacks the glycophospholipid. All ALP bound to bacteria to some extent although placenta ALP exhibited the lowest enzyme activity as well as lowest binding to bacteria. This result supported our belief that certain degrees of glycosylation are better binders for bacteria.

Polylysine-conjugated intestinal ALP was also found to bind bacteria. The conjugation of ALP with a non-glycated peptide was not found to inhibit binding to bacteria and could provide linker arms for labels.

EXAMPLE 5

Bacteria Assay in Presence of Carbohydrates, Polysaccharides, Glycopeptides and Lectins

Bacterial cells (1 to 4.5×10⁷ cells/mL) were washed twice with water after centrifugation to separate cells into a packed pellet from the supernatant liquid. The washed cells in pellet form were suspended in 20 μl of EPPS buffer (50 mM at pH 8.0) and 30 μL of water. Hemoglobin (20 μg) was added as a blocking additive. Alkaline phosphatase (ALP) (100 mUnits) from bovine intestine and 15 μg of simple carbohydrates or proteoglycan or lectins, were added.

The mixture of glycated protein and bacterial cells was left at 25° C. for 15 minutes. The mixture was then centrifuged at 30,000 rpm for 30 minutes after which the bacterial cells formed a pellet at the bottom of the tube and were washed with water 4-5 times (50 μL). Centrifugation allows separation of glycoprotein bound to the bacteria cells from unbound glycated protein(s).

After washing, the bacterial pellets were suspended in 50 μL of sodium tetraborate buffer (25 mM at pH 9.5). A 5 uL aliquot of the suspension was assayed for detection of ALP binding by adding 5 μL of para-nitrophenol phosphate (PNPP, 100 mM), 50 μL sodium borate buffer (25 mM at pH 9.0) and 140 μL of water. The hydrolysis of the PNPP substrate resulted in a yellow color. The color is read at 405 nm using a ELISA plate reader between 15-30 min and the absorbance is directly proportional to the amount of ALP bound to the bacteria cell adhesions for glycated groups.

The binding of ALP to bacteria was shown by an absorbance of 1.8 to 2.0 in Table 3 in the absence of carbohydrates, proteoglycans, and lectins. The monosaccharides (simple carbohydrates) including Glucose, Mannose, Galactose and Sialic acid did not produce any effect on bacteria binding of ALP (all sources). Therefore simple carbohydrates are not involved in the binding and are not suitable as bacterial binders for attachment to detection labels. This also supports the need for glycopeptides or glycoproteins as binders rather than simple glyco-units.

Polysaccharides weakly inhibited the bacteria binding of ALP to a degree depending on the repeating carbohydrate unit. These results show that polysaccharides are involved in the binding of bacteria with ALP. Polysaccharides with N-acetylgalactosamine were more inhibitory and likely contained residual peptide units. By contrast lipopolysaccharide (LPS) was without any effect for the sources tested (B4 and B8 from 2 different serotypes of E. coli). Lipopolysaccharide contains Lipid A and O-antigen on the outer structure and does not expose its polysaccharide core.

Lipoteichoic acid is an example of polysaccharides with repeating carbohydrate and amino acid (Hyl) units that bind the peptidoglycan structure (PG) of bacteria. The structure of the polysaccharide varies with the source of LTA. Structures with and without N-acetylglucosamine are known. In our results LTA (S. sanguis) strongly inhibits the ALP binding to bacteria, whereas, depending on the source, varying or lack of inhibition was observed. Teichoic acid with repeating carbohydrate and amino acid (Hyl) units itself was found equally inhibitory. This supports our belief that the binding of glycopeptides to bacteria involves binding to the peptidoglycan structure (PG) of bacteria. The Teichoic acid effectively competed for PG binding better than ALP.

Lectins are proteins found in plant seeds that bind polysaccharides and monsaccharides attached to peptides. As seen in Table 3 lectins inhibited the bacteria binding of ALP depending on the polysaccharide unit that the lectin bound. These results also support the involvement of carbohydrate and peptide components in the binding of bacteria and the ALP. The lectin binds the glyco group of ALP and prevents it from reacting with bacteria. Since several of the lectins are active but only bind one type of glyco group, several types of glyco peptide groups can cause binding of ALP to bacteria. Lectins that bind Sialic Acid were particularly inhibitory to ALP binding, supporting the presence of sialic acid as a preferred carbohydrate.

TABLE 3
Additional carbohydrates, proteoglycan, and lectins	E. coli	S. faec.
None	1.8	2.0
Simple carbohydrate
Glucose (β-D-Glucose)	1.8	2.4
Galactose (Gal or β-D-Galactose)	2.0	2.0
Fucose	2.0	2.3
Mannose (Man)	1.7	2.4
Sialic Acid (N-Acetyleneuaminic Acid)	2.0	1.7
Muramic Acid	1.8	2.1
GlcNAc (N-Acetyl-β-D-Glucosamine)	2.0	2.0
GalNAc (N-Acetyl-β-D-Galactosamine)	1.8	1.9
Glucuronic acid	1.9	2.0
Iduronic acid	1.9	2.0
Polysacharide
Chondroitin sulfate A	1.1	1.3
(repeating GalNAc & glucuronic)
Chondroitin sulfate B	0.9	0.5
(repeating GalNAc & iduronic acid)
Hyaluronic Acid	1.8	2.0
(repeating GlcNAc & glucuronic acid)
Lipopolysaccharide	1.8	2.0
Glycopeptide
Lipoteichoic acid	0.2	0.2
(from S. sanguis)
Lectins that bind glycopeptides
Euonymus Europeus (Gal-Gal)	1.6	1.8
Bauhinia Purpurea (Gal-GalNAc)	0.3	0.4
Maackia Amurensis (Sialic Acid)	0.1	0.1
Concanavalin A (Man, Glc)	0.0	0.1
Caragana Arborescens (GalNAc)	0.8	1.0

In summary, the binding of ALP as with other glycoproteins/glycopeptides (Table 2) is not blocked by simple carbohydrates but it is by polysaccharides, glycopeptides, and lectins (Table 3). From these results, it can be concluded that glycated proteins did bind to bacteria, while non-glycated proteins did not. Furthermore, simple carbohydrates did not bind to the bacteria. Binding is through the carbohydrate, requires a peptide and occurs with the peptidoglycan. It can be concluded that N-acetyl galactosamine (GalNAc) and Sialic Acid are the more active glycosidic groups. This is supported by the results with lectins, see Bauhinia Purpurea and Caragana Arborescens and polysaccharides, see Chondroitin sulfate A and B.

A glycated protein or glycated peptide can be attached to a label or as part of the label in several ways. The data in Example 5 shows that the glycated portion can be a polysaccharides or a monosaccharide attached to at least one peptide. Examples of polysaccharides or monsacharides include those in Table 2 & 3.

EXAMPLE 6

Alternative Separation Method of Glycated Proteins Bound to Bacteria

Bacteria bound to alkaline phosphatase (ALP) can be separated using a membrane (low protein binding Nylon 66 Loprodyne) on backed microtiter plates (Nunc Nalge International).

The loprodyne-membrane-backed plates were treated with 1 or 2% detergent (Tween 20 or TritonX305) in water or buffers (TBS: Tris, 25 mM, pH 7.6 containing 150 mM NaCl or KCO3: 0.1M, pH 9.6) overnight at room temperature. Blocking solutions were vacuum filtered. Bacteria suspensions (10⁷ cells, 100 μl) in saline were combined with 50 μl EPPS buffer (0.05M, pH 8.1) and 50 μl H₂O containing 20 mU ALP. The combined solution was incubated for 15 min at 37° C. on a shaker and then added to the loprodyne-membrane-backed plate.

The solution was vacuum filtered leaving bacteria adhered on the membrane and then washed twice with 2% Tween20 in water. To the washed membrane, 200 μl of H₂O with 50 μl Glycine (0.05M, pH 10.4) and containing 1 mM PNPP were added and the color formed due to the bacteria bound ALP read at 405 nm.

TABLE 4
Condition	Bacteria Binding to ALP (O.D. at 405 nm)
ALP concentration	1.0	mU	2.0	mU	5.0	mU
No Bacteria	0.04		0.05		0.16
Plus Bacteria	0.13		0.30		0.83

The separation of E. Coli with bound ALP from unbound ALP is shown by a size exclusion membrane in Example 6 and by centrifugation in Examples 1-5. The size of E. Coli is 1×1×2 μm and any membrane, filter or device trapping particles of this size would be acceptable. These include microfluidic devices, filters, column chromatography and chromatography strips. The mass of E. Coli is 1.6×10⁻¹² gm/cell and any membrane, filter or device trapping a mass of this size would be also acceptable.

EXAMPLE 7

Effect of Divalent Cations in Protein Binding to Bacteria

Bacterial cells (1 to 4.5×10⁷ cells/mL) were washed twice with water after centrifugation to separate cells into a packed pellet from the supernatant liquid. The washed cells in pellet form were suspended in 20 μL of EPPS buffer (50 mM at pH 8.0) and 30 μL of water. Bovine intestinal alkaline phosphatase (ALP) (2 μg or 10,000 Units) was added and 0.2 mM of several cations.

The mixture of glycated protein and bacterial cells was left at 25° C. for 15 minutes. The mixture was then centrifuged at 30,000 rpm for 30 minutes after which the bacterial cells formed a pellet at the bottom of the tube and were washed with water 4-5 times (50 μL). Centrifugation allows separation of glycoprotein bound to the bacteria cells from unbound glycated protein(s).

After washing, the bacterial pellets were suspended in 50 μL of borate buffer (25 mM at pH 9.0). A 5 μL aliquot of the suspension was assayed for detection of ALP binding by adding 5 μL of para-nitrophenol phosphate (PNPP, 100 mM), 50 μL sodium borate buffer (25 mM at pH 9.0) and 140 μL of water. The hydrolysis of the PNPP substrate resulted in a yellow color. The color was read at 405 nm using an ELISA plate reader between 15-30 min; the absorbance is directly proportional to the amount of ALP bound to the bacteria cell.

	TABLE 5
	O.D. at 405 nm
	Conditon	No ALP	With ALP
No. cation	0.18	0.30
+CaCl2 (1 mM)	0.23	0.36
+MgCl2 (1 mM)	0.20	0.44
+ZnCl2 (0.2 mM)	0.23	0.53

As seen in Table 5, Zn²⁺ (0.2 mM) resulted in significantly higher binding of ALP to the bacteria. Concentration dependent binding study has been performed in the presence of increasing concentration of zinc with S. faecalis strain as shown in FIG. 11. Result indicated that optimum binding occurs at 1 mM zinc concentration. The studies have been continued with different strains of bacteria in the presence of 1 mM Zn²⁺ and the ALP binding could be monitored even at 10⁵ bacteria concentration (FIG. 12).

EXAMPLE 8

Effect of Various Cation on ALP Binding to Bacteria

Bacterial cells (1 to 4.5×10⁷ cells/mL) were washed twice with water after centrifugation to separate cells into a packed pellet from the supernatant liquid. The washed cells in pellet form were suspended in 20 μL of EPPS buffer (50 mM at pH 8.0) and 30 μL of water. Bovine intestinal alkaline phosphatase (ALP) (2 μg or 10,000 Units) was added and 0.2 mM of each cation.

The mixture of glycated protein and bacterial cells was left at 25° C. for 15 minutes. The mixture was then centrifuged at 30,000 rpm for 30 minutes after which the bacterial cells formed a pellet at the bottom of the tube and was washed with water 4-5 times (50 μL). Centrifugation allows separation of glycoprotein bound to the bacteria cells from unbound glycated protein(s).

After washing, the bacterial pellets were suspended in 50 μL of borate buffer (25 mM at pH 9.0). A 5 μL aliquot of the suspension was assayed for detection of ALP binding by adding 5 μL of para-nitrophenol phosphate (PNPP, 100 mM), 50 μL sodium borate buffer (25 mM at pH 9.0) and 140 μL of water. The hydrolysis of the PNPP substrate resulted in a yellow color. The color was read at 405 nm using an ELISA plate reader between 15-30 min; the absorbance is directly proportional to the amount of ALP bound to the bacteria cell.

Zinc dependency of all the protein binding to bacterial cell wall had been observed as mentioned before. The effect of various cations (2 mM) on the binding of bovine intestinal mucosa ALP (Biozyme) to different bacteria is shown in FIG. 13. In addition to zinc, Cu²⁺, Fe²⁺, and Fe³⁺, and Co⁺² also seem to stimulate ALP-binding in both Gram-positive and Gram-positive strains of bacteria (Sf—Staph. faec.; Ec: E. coli). FIG. 13 also indicates total inhibition of ALP activity in the presence of EDTA (10 mM). Zinc had been used for continuing ALP binding studies. Alkaline phosphatase binding to bacteria seems to be very dependent on the presence of cations as seen in FIG. 13. The data in FIG. 14 shows the binding of various glycated proteins in absence and presence of zinc which clearly demonstrates cation dependency of all the proteins tested for binding to both Gram-positive and Gram-negative bacterial cell wall. The amount of ALP used for this study was so small it can only be detected by measuring enzymatic activity.

EXAMPLE 9

Optimum Conditions for Concentration of Zn in ALP Binding

The human placental ALP activity is comparable to ALP from other sources when assayed in glycine buffer as seen in FIGS. 15-16. Among three cations effective for binding of ALP to the bacteria, zinc was the best metal when the ALP-bound bacteria (both Staph and E. coli) were assayed in glycine buffer, pH 10.0 (FIGS. 17-18). The binding was conducted at pH 8.0 in EPPS buffer.

In FIGS. 15-18, the following abbreviations are used:

• • B1BZ=bovine intestinal from a first vendor
  • B1Si=bovine intestinal from a second vendor
  • HPL=human placenta
  • Bact=bacterial

REFERENCES

• 1. Fries E, Blom A M. Bikunin—not just a plasma proteinase inhibitor. International Journal of Biochemistry & Cell Biology 2000;32(2):125-137.
• 2. Pugia M J, Lott J A. Pathophysiology and diagnostic value of urinary trypsin inhibitors. Review. Clin Chem Lab Med. 2004 in-press.

3. Pugia M J, Takemura T, Kuwajima S, Suzuki M, Cast T K., Profit J A, Schulman L S, Ohta Y, Lott J A. Clinical utility of a rapid test for uristatin. Clinical Biochemistry 2002;35(2):105-110

• 4. Jortani S A, Pugia M J, Elin R J, Thomas M, Womack E P, Cast T, Valdes R Jr; A sensitive non-invasive marker for diagnosis of infection and inflammation. J Clin Lab Anal 2004;18:289-295.
• 5. Pugia M J, Sommer R, Corey P, et al. The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections. Clinica Chimica Acta 2004;341:73-81.
• 6. Kato Y, Kudo M, Shinkawa T, Mochizuki H, Isaji M, Shiromizu, I, Hoshida K. Role of O-linked carbohydrate of human urinary trypsin inhibitor on its lysosomal membrane-stabilizing property. Biochemical and Biophysical Research Communications 1998;243(2):377-383.
• 7. Hochstrasser K, Schoenberger O L, Rossmanith I, Wachter E. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor. V. Attachments of carbohydrates in the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie 1981;362(10): 1357-62.
• 8. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Terao T. Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochimica et Biophysica Acta 2001;1547(1):26-36.
• 9. De Graaf T W, Van der Stelt M E, Anbergen M G, van Dijk W. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha-1-acid glycoprotein (Orosomucoid) in human sera. J Exp Med 1993;177:657-66.
• 10. Cioci G, Rivet A, Koca J, Serge P. Conformational analysis of complex oligosaccharides: the CICADA approach to the uromodulin O-glycans. Carn Res 2004:339;949-59.
• 11. Fukuoka S I, Kobayashi K I. Analysis of the C-terminal structure of urinary Tamm-Horsfall protein reveals that the release of the glycosyl phosphatidylinositol-anchored counter part from the kidney occurs by phenylalanine-specific proteolysis. Biochem Biophys Res Commun 2001;289:1044-8.
• 12. Afonso A A M, Charlwood P A, Marshall R D. Isolation and characterization of glycopeptides digests for human Tamm-Horsfall Glycoportins Carb Res 1981;89:309-19.
• 13. Azuma Y, Murata M, Matsumoto K. Alteration of sugar chains on alpha-1-acid glycoprotein secreted following cytokine stimulation of HuH-7cells in vitro. Clin Chem Acta 2000;294:93-103.
• 14. Nishi K, Maruyama T, Halsall H B, Handa T, Otagiri M.Binding of alpha-1-acid glycoprotein to Membrane Results in a Unique Structural Change and Ligand Release. Biochem 2004;43:10513-9.
• 15. Kopeck V, Ettrich R, Hofbauerova K, Baumruk V. Structure of human alpha-1-acid glycoprotein and its high-affinity binding site. Biochem Biophys Res Comm 2003;300:41-46.
• 16. Higai K, Azuma Y, Aoki Y, Matsumoto K. Altered glycosylation of alpha-1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin Chim Acta 2003;329:117-25.
• 17. Blom E, Ali M M, Mortensen B, Huseby N E Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates Clin Chim Acta 1998;270:125-137
• 18. Fukushima K, Ikehara Y, Kanai_M, Kochibe N, Kuroki M, Yamashita K A N-Acetylglucosaminyl Phosphate Diester Residue Is Attached to the Glycosylphosphatidylinositol Anchor of Human Placental Alkaline Phosphatase JBC 2003;278 (38):36296-36303.
• 19. Kunin C M. Detection, Prevention, and Management of Urinary Tract Infection. Lea and Febiger. Philadelphia Pa. 4ed 1987 p39, 140-5, 316.
• 20. Strauss J H, Strauss E G. Viruses and human disease. Academic press. San Diego Calif. 1^st ed 2002.
• 21. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Review. Biochim Biophys Acta 2000;1482:157-71
• 22. Cavallone D, Malagolini N, Monti A, Wu X R, Serafini-Cessi F. Variation of high mannose chains to Tamm-Horsfall glycoprotein confers differential binding to type 1-fimbriated Escherichia coli. J Biol Chem 2004;279:216-22.

Claims

1. A method for measuring the bacteria content of fluids comprising: a. binding an effective amount of a glycoprotein or glycopeptide with bacteria contained in a sample of fluid, said glycoprotein or glycopeptide having a binding constant to bacteria of at least 106 and at least 100 binding sites, said glycoprotein or glycopeptide consisting of proteins or peptides linked through nitrogen or oxygen bonds to glycosidic groups selected from the group consisting of Gal, GlcNAc, SA, Man, Glc, GalNAc and combinations thereof. b. separating excess unbound glycoprotein or glycopeptide from said fluid sample after reacting said glycoprotein or glycopeptide with bacteria in said sample in step (a); c. measuring the amount of said glycoprotein or glycopeptide remaining after separating said excess unbound glycoprotein or glycopeptide in step (b) by detecting a label added to said glycoprotein or glycopeptide before the binding with bacteria or adding a label after separating said excess unbound glycoprotein or glycopeptide; and d. determining the bacteria content of said sample as related to the amount of said label measured in step (c).

2. The method of claim 1 wherein said glycoprotein or glycopeptide is at least one member of the group consisting of serum proteins, immunoglobulins, oxygen binding proteins, intra cellular enzymes, secreted enzymes, and inhibitors.

3. The method of claim 1 wherein said glycoprotein or glycopeptide comprises sialic acid.

4. The method of claim 2 wherein said glycoprotein is a serum protein selected from the group consisting of albumin, prealbumin, transferrin, retinol binding protein, bikunin, uristatin, alpha-1-Glycoprotein, alpha-1-antitrypsin, Tamm-Horsfall protein, beta-2-glycoprotein and fragments thereof.

5. The method of claim 2 wherein said glycoprotein is an immunoglobulin selected from the group consisting of IgG, IgA, IgM, IgD, and gG.

6. The method of claim 2 wherein said glycoprotein is a secreted enzyme or inhibitor selected from the group consisting of protease inhibitors, alpha-1-microglobulin, typsinogen, lysozyme, and alpha-1-acid glycoprotein.

7. The method of claim 2 wherein said glycoprotein or glycopeptide is an enzyme selected from the group consisting of alkaline phosphatase, acid phosphatase, fucosidase, mannosidase, hexamimidase, alpha-galactosidase, phospholipase, hyaluronidase, glucocerebrosidase, hydrolase, arylsulfatase A, amylases, cellobiohydrolase, and peroxidase.

8. The method of claim 7 wherein said enzyme is alkaline phosphatase (ALP).

9. The method of claim 8 wherein said ALP is intestinal ALP.

10. The method of claim 1 wherein said glycoprotein or glycopeptide is teichoic acid or lipoteichoic acid.

11. The method of claim 1 wherein said glycoprotein or glycopeptide has a label selected from the group consisting of colorimetric, radioactive, fluorescent, electroactive, chemi-luminescent, enzyme, antibody, and particulate labels.

12. The method of claim 11 wherein said label is a particle selected from the group consisting of latex beads, gold sols, and antibodies.

13. The method of claim 12 wherein said label is a particle selected from the group consisting of antibodies to the glycoprotein with or without conjugation to particles, enzymes, and gold sols.

14. The method of claim 1 wherein said label is comassie brilliant blue.

15. The method of claim 1 further comprising adding to said sample blocking compounds selected from the group consisting of polymers, non-glycated proteins, non-glycated polypeptides, and polysaccharides.

16. The method of claim 1 further comprising at least one cation capable of increasing the binding of said glycoprotein or glycopeptide to bacteria.

17. The method of claim 16 wherein said cation is at least one member of the group consisting of zinc, copper, iron, and cobalt.

18. The method of claim 17 wherein said cation is zinc.

19. A method of measuring the bacteria content of fluids comprising; (a) binding an effective amount of a glycoprotein or glycopeptide with bacteria contained in a sample of fluid, said glycoprotein or glycopeptide consisting of at least one member of the group consisting of albumin, prealbumin, bikunin, uristatin, Tamm-Horsfall glycoprotein, alpha-1-Antitrypsin, Transferrin, Retinol Binding Protein, alpha-1-acid glycoprotein, beta-2-Glycoprotein, and IgG, IgA, IgM, and their fragments; (b) separating excess unbound glycoprotein or glycopeptide from said fluid sample after reacting said glycoprotein or glycopeptide with bacteria in (a); (c) measuring the amount of said glycoprotein or glycopeptide remaining after separating said excess unbound glycoprotein or glycopeptide in (b) by detecting a label added to said glycoprotein or glycopeptide before binding with bacteria or adding a label after separating said excess unbound glycoprotein or glycopeptide; and (d) determining the bacteria context of said sample as related to the amount of said label measured in (c).

20. A method of claim 19 wherein said separating of (b) is carried out by centrifuging or filtration.

21. A method of claim 1 wherein said glycoprotein or glycopeptide is a member of the group of lectins consisting of Bauhimia Purpurea, Maackia Amurensis, Concanavalin A, and Caragana Arborescens.